SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 45.37 |
Enterprise Value ($M) | 10.73 |
Book Value ($M) | 14.30 |
Book Value / Share | 5.47 |
Price / Book | 3.17 |
NCAV ($M) | 14.15 |
NCAV / Share | 5.42 |
Price / NCAV | 3.21 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -1.27 |
Return on Assets (ROA) | -1.68 |
Return on Equity (ROE) | n/a |
Liquidity (mrq) | |
---|---|
Quick Ratio | 7.34 |
Current Ratio | 7.34 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 38.11 |
Assets | 38.27 |
Liabilities | 23.96 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 1.02 |
Operating Income | -24.18 |
Net Income | -18.46 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -25.31 |
Cash from Investing | 0.00 |
Cash from Financing | 52.61 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G | Fmr Llc | 7.32 | ||
13D/A | MacAndrews & Forbes Inc. | 50.30 | -97.50 | |
13D | Baker Bros. Advisors Lp | 4.99 | ||
13D | Samsara BioCapital, L.P. | 10.40 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
1,272 | 7,046 | 18.05 | |
4,164 | 17,613 | 23.64 | |
1,712 | 16,245 | 10.54 | |
(click for more detail) |
Similar Companies | |
---|---|
VRPX – Virpax Pharmaceuticals, Inc. | VSTM – Verastem, Inc. |
VTGN – Vistagen Therapeutics, Inc. | VXRT – Vaxart, Inc. |
VYNE – VYNE Therapeutics Inc. |
Financial data and stock pages provided by
Fintel.io